Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: Selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 3, 2002, Pages 731-738

  Maguire, Michael ^a   Shortino, Denise ^a   Klein, Astrid ^a   Harris, Wendy ^a   Manohitharajah, Varsha ^a   Tisdale, Margaret ^a   Elston, Robert ^a   Yeo, Jane ^a   Randall, Sharon ^a   Xu, Fan ^a   Parker, Hayley ^a   May, Jackie ^a   Snowden, Wendy ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; GENE PRODUCT; INDINAVIR; ISOLEUCINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VALINE; ZALCITABINE; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; VIRUS GENOME; VIRUS RESISTANCE;

CARBAMATES; CLONING, MOLECULAR; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTAGENESIS, SITE-DIRECTED; NUCLEOSIDES; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SULFONAMIDES;

EID: 0036174439     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.3.731-738.2002     Document Type: Article

References (36)

1. Resistance to human immunodeficiency virus type 1 protease inhibitors
2. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
3. Resistance to HIV protease inhibitors
4. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
5. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
6. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347
7. Mechanisms of virologic failure in previously untreated. HIV-infected patients from a trial of induction-maintenance therapy
8. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
9. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632
10. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
11. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
12. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an international AIDS society - USA panel
13. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
14. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
15. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
16. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects
17. Absence of zidovudine resistance in antiretroviral-naïve patients following zidovudine/lamivudine/protease inhibitor combination therapy: Virological evaluation of the AVANTI 2 and AVANTI 3 studies
18. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
19. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection
20. Unique resistance profile of the protease inhibitor amprenavir (141W94) observed in vitro and in the clinic
21. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
22. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
23. In vitro selection and characterization of VX-478 resistant HIV-1 variants
24. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
25. HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays
26. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors
27. Human immunodeficiency virus type 1 protease inhibitors: Evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site
28. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations
29. Low level of cross-resistance to amprenavir (141W94) in samples from patients pre-treated with other protease inhibitors
30. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)
31. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors
32. Evolution of resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies
33. The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance
34. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
35. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
36. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to APV